GH Research (GHRS) Gains from Investment Securities (2021 - 2026)
GH Research (GHRS) posted quarterly Gains from Investment Securities of -$2.1 million for Q4 2025, up 20.28% year-over-year from -$1.8 million in Q4 2024, and down 195.21% quarter-over-quarter from $2.2 million in Q3 2025.
Powered by 
Analysis
GH Research (GHRS) Gains from Investment Securities (2021 - 2026) Analysis & Trends
GH Research's Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$2.1 million for Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 20.28% year-over-year to -$2.1 million; the TTM figure through Dec 2025 stood at -$1.8 million (up 17.66% YoY), while the FY2025 annual figure was -$1.8 million, up 17.66% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$2.1 million, down from $2.2 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $15.6 million in Q4 2022, with the low at -$15.5 million in Q3 2022.
- The 5-year median for Gains from Investment Securities is $174500.0 (2023), against an average of -$524937.5.
- Peak annual rise in Gains from Investment Securities reached 1163.59% in 2024, while the deepest fall reached 1511.11% in 2024.
- GH Research's Gains from Investment Securities stood at -$2.5 million in 2021, then jumped by 717.98% to $15.6 million in 2022, then slumped by 98.79% to $189000.0 in 2023, then tumbled by 1511.11% to -$2.7 million in 2024, then rose by 20.28% to -$2.1 million in 2025.
- Business Quant data shows GHRS's Gains from Investment Securities at -$2.1 million in Q4 2025, $2.2 million in Q3 2025, and -$2.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.73 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Dec 31, 2025 | -179,000.00 |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | -2.50 Mn |
| Mar 31, 2025 | 642,000.00 |
| Dec 31, 2024 | -23,000.00 |
| Sep 30, 2024 | -334,000.00 |
| Jun 30, 2024 | 955,000.00 |
| Mar 31, 2024 | -1.32 Mn |
| Dec 31, 2023 | 189,000.00 |
| Sep 30, 2023 | 184,000.00 |
| Jun 30, 2023 | 596,000.00 |
| Mar 31, 2023 | -246,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Sep 30, 2022 | 9.33 Mn |
| Jun 30, 2022 | -7.08 Mn |
| Mar 31, 2022 | -2.24 Mn |
| Dec 31, 2021 | -5.92 Mn |
| Sep 30, 2021 | 3,000.00 |